Clinical Trial

A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To assess the ability of lamivudine to lower the levels of neurocognitive impairment biomarkers in the plasma of patients with MCI and positive AD biomarkers in a 24 weeks-treatment period. To assess the incidence, nature, and severity of Treatment Emergent Adverse Events (TEAE).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-07-19; most recent amendment 2025-11-27.
Status change: Recruiting → Active, Not Recruiting 2025-06-11
Status change: Active, Not Recruiting → Recruiting 2024-10-30
Status change: Not Yet Recruiting → Active, Not Recruiting 2024-10-14
Trial Details
NCT Number NCT06519357
Lead Sponsor Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Collaborators: IrsiCaixa
Conditions Mild Cognitive Impairment
Enrollment 23 participants
Start Date 2024-10-28
Primary Completion 2025-09-05 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2025-12-04